The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Evaluation of teriparatide treatment in adults with osteogenesis imperfecta
Open accessAbstract
BACKGROUND: Adults with osteogenesis imperfecta (OI) have a high risk of fracture. Currently, few treatment options are available, and bone anabolic therapies have not been tested in clinical trials for OI treatment. METHODS: 79 adults with OI were randomized to receive 20 μg recombinant human parathyroid hormone (teriparatide) or placebo for 18 months in a double-blind, placebo-controlled trial. The primary endpoint was the percent change in areal bone mineral density (aBMD) of the lumbar spine (LS), as determined by dual-energy X-ray absorptiometry. Secondary endpoints included percent change in bone remodeling markers and vertebral volumetric BMD (vBMD) by quantitative computed tomography, estimated vertebral strength by finite element analysis, and self-reported fractures. RESULTS: Compared with the placebo group, the teriparatide group showed increased LS aBMD (6.1% ± 1.0% vs. 2.8% ± 1.0% change from baseline; P < 0.05) and total hip aBMD (2.6% ± 1.0% vs. -2.4% ± 1.0% change; P < 0.001). Vertebral vBMD and strength improved with teriparatide therapy (18% ± 6% and 15% ± 3% change, respectively), but declined with placebo (-5.0% ± 6% and -2.0% ± 3% change; P < 0.05 for both comparisons). Serum procollagen type 1 N-terminal propeptide (P1NP) and urine collagen N-telopeptide (NTx) levels increased with teriparatide therapy (135% ± 14% and 64% ± 10% change, respectively). Teriparatide-induced elevation of P1NP levels was less pronounced in severe forms of OI (type III/IV) compared with the milder form (type I). Type I OI patients exhibited robust BMD increases with teriparatide; however, there was no observed benefit for those with type III/IV OI. There was no difference in self-reported fractures between the 2 groups. CONCLUSIONS: Adults with OI, particularly those with less severe disease (type I), displayed a teriparatide-induced anabolic response, as well as increased hip and spine aBMD, vertebral vBMD, and estimated vertebral strength. Trial registration. Clinicaltrials.gov NCT00131469. Funding. The Osteoporosis Imperfecta Foundation, Eli Lilly and Co., the National Center for Advancing Translational Science (NCATS) at the NIH (grant no. UL1RR024140), and the Baylor College of Medicine General Clinical Research Center (grant no. RR00188).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Forlino, A., Tani, C., Rossi, A., Lupi, A., Campari, E., Gualeni, B., Bianchi, L., Armini, A., Cetta, G., Bini, L., et al. (2007) · PROTEOMICS · doi:10.1002/pmic.200600919 · Cited by 54
Cited by
Marini, J. C., Forlino, A., Bächinger, H. P., Bishop, N. J., Byers, P. H., Paepe, A. D., Fassier, F., Fratzl-Zelman, N., Kozloff, K. M., Krakow, D., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.52 · Cited by 842
Bisphosphonate therapy for osteogenesis imperfecta
Dwan, K., Phillipi, C. A., Steiner, R. D., & Basel, D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005088.pub4 · Cited by 405
Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta
Grafe, I., Yang, T., Alexander, S., Homan, E. P., Lietman, C., Jiang, M. M., Bertin, T., Munivez, E., Chen, Y., Dawson, B., et al. (2014) · Nature Medicine · doi:10.1038/nm.3544 · Cited by 306
Self-citationSkeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta
Jeong, Y., Daghlas, S. A., Xie, Y., Hulbert, M. A., Pfeiffer, F. M., Dallas, M. R., Omosule, C. L., Pearsall, R. S., Dallas, S. L., & Phillips, C. L. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3473 · Cited by 36
Sclerostin inhibition in rare bone diseases: Molecular understanding and therapeutic perspectives
Xiaohui, T., Wang, L., Yang, X., Jiang, H., Zhang, N., Zhang, H., Li, D., Li, X., Zhang, Y., Wang, S., et al. (2024) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2024.05.004 · Cited by 10
“However, no benefit was observed in patients with severe OI (type III/IV), nor was a significant reduction in the number of self-reported fractures observed [52].”
BackgroundMethod
Metadata
- Authors
- Orwoll, E. S., Shapiro, J., Veith, S., Wang, Y., Lapidus, J., Vanek, C., Reeder, J. L., Keaveny, T. M., Lee, D. C., Mullins, M. A., Nagamani, S. C. S., & Lee, B.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-01-27
- Volume
- 124
- Issue
- 2
- Pages
- 491-498
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2088531604
- Cited by
- 210
- References
- 2
- FWCI
- 20.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. https://app.cochat.ai/papers/10.1172/jci71101
- The paper
- Orwoll, E. S., Shapiro, J., Veith, S., Wang, Y., Lapidus, J., Vanek, C., Reeder, J. L., Keaveny, T. M., Lee, D. C., Mullins, M. A., Nagamani, S. C. S., & Lee, B. (2014). Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. Journal of Clinical Investigation. https://doi.org/10.1172/jci71101
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.